UB Paderborn / Katalog / Suche / in CDI

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD

Molecular therapy. Methods & clinical development, 2020-09, Vol.18, p.345-353

2020

Volltextzugriff (PDF)

Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates

Translational vision science & technology, 2021-01, Vol.10 (1), p.34-34

2021

Volltextzugriff (PDF)

ZFN-Mediated Gene Targeting at the Albumin Locus in Liver Results in Therapeutic Levels of Human FIX in Mice and Non-Human Primates

Blood, 2015-12, Vol.126 (23), p.200-200

2015

Volltextzugriff (PDF)

Engineering Goals for Future Thoracic Endografts—How Can We Make Them More Effective?

Progress in cardiovascular diseases, 2013-07, Vol.56 (1), p.92-102

2013

Volltextzugriff (PDF)

Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration

Molecular therapy, 2019-01, Vol.27 (1), p.118-129

2019

Volltextzugriff (PDF)

Genetic induction of a releasable pool of factor VIII in human endothelial cells

Arteriosclerosis, thrombosis, and vascular biology, 2000-12, Vol.20 (12), p.2689

2000

Volltextzugriff (PDF)

Variability of Thrombosis among Homozygous Siblings with Resistance to Activated Protein C Due to an Arg-to-Gln Mutation in the Gene for Factor V

The New England journal of medicine, 1994-12, Vol.331 (23), p.1559-1562

1994

Volltextzugriff (PDF)

Animal testing of retroviral-mediated gene therapy for factor VIII deficiency

Thrombosis and haemostasis, 1999-08, Vol.82 (2), p.555

1999

Volltextzugriff (PDF)

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema

Journal of ocular pharmacology and therapeutics, 2021-04, Vol.37 (3), p.181

2021

Volltextzugriff (PDF)

Generation of Retroviral Packaging and Producer Cell Lines for Large-Scale Vector Production and Clinical Application: Improved Safety and High Titer

Molecular therapy, 2000-09, Vol.2 (3), p.262-275

2000

Volltextzugriff (PDF)

Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene : No evidence of germ line transduction

Human gene therapy, 2000-12, Vol.11 (18), p.2529-2540

2000

Volltextzugriff (PDF)

Development of an Optimized rAAV2/6 Human Factor 8 cDNA Vector Cassette for Hemophilia a Gene Therapy

Blood, 2016-12, Vol.128 (22), p.1173-1173

2016

Volltextzugriff (PDF)

The Resistance of Retroviral Vectors Produced from Human Cells to Serum Inactivation In Vivo and In Vitro Is Primate Species Dependent

Journal of Virology, 1999-08, Vol.73 (8), p.6708-6714

1999

Volltextzugriff (PDF)

Sustained Patency and Clinical Improvement Following Treatment of Atherosclerotic Iliac Artery Disease Using the Assurant Cobalt Iliac Balloon-Expandable Stent System

Journal of endovascular therapy, 2013-02, Vol.20 (1), p.94-103

2013

Volltextzugriff (PDF)

Activated protein C resistance caused by Arg506Gln mutation in factor Va

The Lancet (British edition), 1994-05, Vol.343 (8909), p.1361-1362

1994

Volltextzugriff (PDF)

Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites (∗)

The Journal of biological chemistry, 1995-10, Vol.270 (41), p.24216-24221

1995

Volltextzugriff (PDF)

Receptors for high molecular weight kininogen on stimulated washed human platelets

Biochemistry (Easton), 1984-12, Vol.23 (26), p.6863-6869

1984

Volltextzugriff (PDF)

Binding of coagulation factor XI to washed human platelets

Biochemistry (Easton), 1986-07, Vol.25 (13), p.3884-3890

1986

Volltextzugriff (PDF)

A two-allele polymorphism in protein C inhibitor with varying frequencies in different ethnic populations

Thrombosis and haemostasis, 1996-01, Vol.75 (1), p.62

1996

Volltextzugriff (PDF)

Possible structural implications of 20 mutations in the protein C protease domain

Thrombosis and haemostasis, 1994, Vol.72 (6), p.869

1994

Volltextzugriff (PDF)

Activated protein C resistance: molecular mechanisms

Thrombosis and haemostasis, 1995-07, Vol.74 (1), p.444

1995

Volltextzugriff (PDF)

Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant

Blood, 1995-04, Vol.85 (7), p.1704-1711

1995

Volltextzugriff (PDF)

Factors Affecting Long-Term Expression of a Secreted Transgene Product after Intravenous Administration of a Retroviral Vector

Molecular therapy, 2001-04, Vol.3 (4), p.516-525

2001

Volltextzugriff (PDF)

Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen

Protein science, 1994-04, Vol.3 (4), p.588-599

1994

Volltextzugriff (PDF)

Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: Patterns revealed by three-dimensional molecular modelling of mutations of the protease domain

Proteins, structure, function, and bioinformatics, 1994-04, Vol.18 (4), p.367-380

1994

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD

Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates

ZFN-Mediated Gene Targeting at the Albumin Locus in Liver Results in Therapeutic Levels of Human FIX in Mice and Non-Human Primates

Engineering Goals for Future Thoracic Endografts—How Can We Make Them More Effective?

Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration

Genetic induction of a releasable pool of factor VIII in human endothelial cells

Variability of Thrombosis among Homozygous Siblings with Resistance to Activated Protein C Due to an Arg-to-Gln Mutation in the Gene for Factor V

Animal testing of retroviral-mediated gene therapy for factor VIII deficiency

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema

Generation of Retroviral Packaging and Producer Cell Lines for Large-Scale Vector Production and Clinical Application: Improved Safety and High Titer

Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene : No evidence of germ line transduction

Development of an Optimized rAAV2/6 Human Factor 8 cDNA Vector Cassette for Hemophilia a Gene Therapy

The Resistance of Retroviral Vectors Produced from Human Cells to Serum Inactivation In Vivo and In Vitro Is Primate Species Dependent

Sustained Patency and Clinical Improvement Following Treatment of Atherosclerotic Iliac Artery Disease Using the Assurant Cobalt Iliac Balloon-Expandable Stent System

Activated protein C resistance caused by Arg506Gln mutation in factor Va

Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites (∗)

Receptors for high molecular weight kininogen on stimulated washed human platelets

Binding of coagulation factor XI to washed human platelets

A two-allele polymorphism in protein C inhibitor with varying frequencies in different ethnic populations

Possible structural implications of 20 mutations in the protein C protease domain

Activated protein C resistance: molecular mechanisms

Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant

Factors Affecting Long-Term Expression of a Secreted Transgene Product after Intravenous Administration of a Retroviral Vector

Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen

Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: Patterns revealed by three-dimensional molecular modelling of mutations of the protease domain

Suchergebnisse filtern